Related Experiment Videos
New drugs for HIV therapy
Roy M Gulick1, Schlomo Staszewski
1Cornell Clinical Trial Unit, Weill Medical College of Cornell University, New York, New York 10024, USA. rgulick@med.cornell.edu
AIDS (London, England)
|April 18, 2003
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record-Based Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Future options for long-acting HIV treatment and prevention.
Current opinion in HIV and AIDS·2024
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
Annals of internal medicine·2024
Long-acting HIV Treatments: Study Design, Logistics, and Access.
Open forum infectious diseases·2024
CD4+ cell count trends after common cancers in people with HIV: a multicohort collaboration.
AIDS (London, England)·2026
Vascular risk drives cognitive decline over 10 years in people aging with well-controlled HIV.
AIDS (London, England)·2026
Development of a Novel, Eco-Friendly Mechanical Cell Lysis Process Using Hollow Fiber Filter for AAV Manufacturing.
Biotechnology and bioengineering·2026
Programmed repair of disease-causing UGA premature termination codons in mammalian brain.
Nucleic acids research·2026
Molecular profiling and functional analyses of umbilical cord mesenchymal stem cell-derived extracellular vesicles for dry eye diseases.
Extracellular vesicles and circulating nucleic acids·2026
Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.
Frontiers in immunology·2026
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
The Journal of clinical and aesthetic dermatology·2026